Regeneron and Sanofi will cut the price of their cholesterol drug Praluent by 60 percent to $5,850 a year, matching an unprecedented move that rival Amgen made with its medicine Repatha, the drug makers said Monday.

The two cholesterol drugs are now becoming an experiment in drug pricing. Praluent and Repatha were once expected to generate more than $1 billion in annual sales each. In 2015, executives at CVS Health, the pharmacy benefit manager, warned that together the medicines, which are given as injections, could cost the U.S. health care system $150 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy